GUIDELINES EQUALITY IMPACT ASSESSMENT FORM:
SCOPING

Guideline title:  Hyperglycaemia

1. Have relevant equality issues been identified during scoping?

No specific sub-groups have been identified however the scope acknowledges that there could be sub groups who would require a different intervention and we plan to explore the supporting evidence in the clinical review and with the GDG.

2. If there are exclusions listed in the scope (for example, populations, treatments or settings) are these justified?

The exclusions listed in the scope do not discriminate any specific groups

3. Have relevant bodies and stakeholders been consulted?

- Yes. We held a stakeholder workshop and the scope went to the wider stakeholder population for full consultation.
- Various stakeholders have noted potential subgroups but not defined any specific evidence base to support this. We have noted in our scope that there may be sub-groups to consider but we have not defined them at this stage.
Signed:

Nicole Elliott  Damien Longson

SCG Associate Director  GDG Chair

Date: August 2010  Date: August 2010

Approved and signed off:

Peter Robb  Sarah Willett

GRP Chair  CCP Lead

Date: September 2010  Date: September 2010